


**Amendments to the Claims:**

Please amend Claims 1-7 and 9 as set forth below. Please cancel claims 8 and 10. Please add new claims 11-17. This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (original) Novel tetrahydropyridine derivatives according to formula (I)



(I)

wherein

X and Y represent independently hydrogen, fluorine or a methyl group; X and Y do not represent both hydrogen at the same time or X and Y may together form a cyclopropyl ring;

W represents a phenyl or heteroaryl ring, the heteroaryl ring being a six-membered and non-fused ring, the phenyl ring and the heteroaryl ring are substituted with V in position 3 or 4;

V represents  $-(CH_2)_r-$ ;  $-A-(CH_2)_s-$ ;  $-CH_2-A-(CH_2)_t-$ ;  $-(CH_2)_s-A-$ ;  $-(CH_2)_2-A-(CH_2)_u-$ ;  $-A-(CH_2)_v-B-$ ;  $-CH_2-CH_2-CH_2-A-CH_2-$ ;  $-A-CH_2-CH_2-B-CH_2-$ ;  $-CH_2-A-CH_2-CH_2-B-$ ;  $-CH_2-CH_2-CH_2-A-CH_2-$ ;  $-CH_2-CH_2-CH_2-CH_2-A-CH_2-$ ;  $-A-CH_2-CH_2-B-CH_2-CH_2-$ ;  $-CH_2-A-CH_2-CH_2-B-CH_2-$ ;  $-CH_2-A-CH_2-CH_2-CH_2-B-$ ;  $-CH_2-CH_2-A-CH_2-CH_2-B-$ ;  $-O-CH_2-CH(OCH_3)-CH_2-O-$ ;  $-O-CH_2-CH(CH_3)-CH_2-O-$ ;  $-O-CH_2-CH(CF_3)-CH_2-O-$ ;  $-O-CH_2-C(CH_3)_2-$

$\text{CH}_2\text{-O-}$ ;  $\text{-O-CH}_2\text{-C(CH}_3)_2\text{-O-}$ ;  $\text{-O-C(CH}_3)_2\text{-CH}_2\text{-O-}$ ;  $\text{-O-CH}_2\text{-CH(CH}_3\text{)-O-}$ ;  $\text{-O-CH(CH}_3\text{)-CH}_2\text{-O-}$ ;  $\text{-O-CH}_2\text{-C(CH}_2\text{CH}_2\text{)-O-}$  or  $\text{-O-C(CH}_2\text{CH}_2\text{)-CH}_2\text{-O-}$ ;

A and B independently represent  $\text{-O-}$ ;  $\text{-S-}$ ;  $\text{-SO-}$  or  $\text{-SO}_2\text{-}$ ;

U represents aryl or heteroaryl;

T represents  $\text{-CONR}^1\text{-}$ ;  $\text{-(CH}_2)_p\text{OCO-}$ ;  $\text{-(CH}_2)_p\text{N(R}^1\text{)CO-}$ ;  $\text{-(CH}_2)_p\text{N(R}^1\text{)SO}_2\text{-}$ ;  $\text{-COO-}$ ;  $\text{-(CH}_2)_p\text{OCONR}^1\text{-}$  or  $\text{-(CH}_2)_p\text{N(R}^2\text{)CONR}^1\text{-}$ ;

$\text{R}^1$  and  $\text{R}^2$  independently represent hydrogen; lower alkyl; lower alkenyl; lower alkynyl; cycloalkyl; aryl-lower alkyl, heteroaryl-lower alkyl or cycloalkyl - lower alkyl;

Q represents lower alkylene or lower alkenylene;

M represents hydrogen; cycloalkyl; aryl; heterocyclyl or heteroaryl;

p is the integer 1, 2, 3 or 4;

r is the integer 3, 4, 5, or 6;

s is the integer 2, 3, 4 or 5;

t is the integer 1, 2, 3 or 4;

u is the integer 1, 2 or 3;

v is the integer 2, 3 or 4;

and in any form including optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as in free acid or base form or pharmaceutically acceptable salts, solvent complexes and morphological forms.

2. Tetrahydropyridine derivatives according to claim 1 wherein X, Y, V, W and U are as defined in general formula (I); T represents -CONR<sup>1</sup>-; Q represents lower alkylene and M represents hydrogen, aryl or heteroaryl.

3. (currently amended) Tetrahydropyridine derivatives according to ~~any of claims claim 1 to 2~~ wherein X, Y, W, T, Q and M are as defined in general formula (I), V represents -CH<sub>2</sub>CH<sub>2</sub>O-; -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>O-; -OCH<sub>2</sub>CH<sub>2</sub>O- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>O- and U is as defined in general formula (I).

4. (currently amended) Tetrahydropyridine derivatives according to ~~any of claims claim 1 to 3~~ wherein X, Y, V, U, T, Q and M are as defined in general formula (I) and W represents a phenyl substituted in -4 position with V.

5. (currently amended) Tetrahydropyridine derivatives according to ~~any of claims claim 1 to 4~~ wherein W, V, U, T, Q and M are as defined in general formula (I) and X and Y together may form a cyclopropyl group.

6. (currently amended) The compounds according to ~~any of claims claim 1 to 5~~ selected from the group consisting of:

8-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-5-aza-spiro[2.5]oct-7-ene-7-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide;

4-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-dimethyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide;

4-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-dimethyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amide;

8-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-5-aza-spiro[2.5]oct-7-ene-7-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-yl-methyl)-amide;

8-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5-azaspiro[2.5]oct-7-ene-7-carboxylic acid cyclopropyl-[2-(2-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide;

4-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-dimethyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid cyclopropyl-[2-(2-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide;

4-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-difluoro-1,2,5,6-tetrahydropyridine-3-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide.

7. (currently amended) A pharmaceutical composition containing at least one compound according to ~~any of claims~~ claim 1 to 6 and pharmaceutically acceptable ~~inert~~ carrier material or adjuvants.

8. (cancelled)

9. (currently amended) A method for the treatment or prophylaxis of diseases which are related to hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis, renal colic, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy, glaucoma, elevated intra-ocular pressure, atherosclerosis, restenosis post angioplasty, complications following vascular or cardiac surgery, erectile dysfunction, hyperaldosteronism, lung fibrosis, scleroderma, anxiety, cognitive disorders, complications of treatments with immunosuppressive agents, and other diseases known to be related to the renin-angiotensin system, comprising the administration to a patient of a pharmaceutically active amount of a five-membered heteroaryl derivative according to ~~any of claims~~ claim 1 to 7.

10. (cancelled)

11. (new) The compound according to claim 1 which is 8-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-5-aza-spiro[2.5]oct-7-ene-7-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide.

12. (new) The compound according to claim 1 which is 4-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-dimethyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide.

13. (new) The compound according to claim 1 which is 4-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-dimethyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-ylmethyl)amide.
14. (new) The compound according to claim 1 which is 8-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]phenyl}-5-aza-spiro[2.5]oct-7-ene-7-carboxylic acid cyclopropyl-(2-methoxy-3-methylpyridin-4-yl-methyl)-amide.
15. (new) The compound according to claim 1 which is 8-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5-azaspiro[2.5]oct-7-ene-7-carboxylic acid cyclopropyl-[2-(2-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide.
16. (new) The compound according to claim 1 which is 4-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-dimethyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid cyclopropyl-[2-(2-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide.
17. (new) The compound according to claim 1 which is 4-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-difluoro-1,2,5,6-tetrahydropyridine-3-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide.